Medication
Saxenda review: liraglutide and daily weight-management care
Saxenda contains liraglutide, a GLP-1 receptor agonist administered daily. It remains a distinct approved weight-management product, with different routines and response rules from weekly injections.
A daily injection is a different commitment
Adult Saxenda treatment starts at 0.6 mg daily, with weekly increases through 1.2, 1.8, and 2.4 mg to the recommended 3 mg daily dose. Escalation is intended to improve gastrointestinal tolerability. The adult maintenance recommendation differs from its starter steps.
The label includes a defined adult response assessment after 16 weeks from initiation: treatment should be discontinued if at least 4% of baseline weight has not been lost. Have the clinician apply this rule and the separate pediatric instructions rather than making decisions from an adult chart alone.
Sources: Saxenda prescribing information
The name of the prescribed product matters
Liraglutide is also used in other products with different indications and dosing. A lower-cost or generic liraglutide offer should identify its approved product and intended use; the ingredient name alone does not establish a Saxenda-equivalent weight-management prescription.
Do not combine Saxenda with another GLP-1 receptor agonist. A switch to weekly treatment or to tablets needs a prescriber-led plan, including what happens to the daily dose and how the new medicine is introduced.
Sources: Saxenda prescribing information
Safety and interruptions
Saxenda has a thyroid C-cell tumor boxed warning and MTC/MEN 2 contraindications. Important concerns include pancreatitis, gallbladder disease, gastrointestinal adverse effects, and dehydration-related kidney injury. Discuss diabetes medicines, pregnancy, and other conditions before starting.
After an interruption, follow the label's restart instructions rather than returning automatically to the prior daily dose. Ask for injection and device training, and avoid sharing pens even when a needle is changed.
Sources: Saxenda prescribing information
Evaluate continuity as well as cost
A daily product uses a different quantity of pens and supplies from weekly treatments. Confirm the prescribed product, expected refill quantity, pharmacy bill, and clinical follow-up cost before comparing monthly advertisements.
Trial results for semaglutide or tirzepatide do not describe expected liraglutide outcomes. The practical decision includes response, tolerability, coverage, and whether you can sustain daily administration.
Sources: Saxenda prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.